Eton Pharmaceuticals, Inc. (ETON) Stock Analysis & Investment Frameworks

Eton Pharmaceuticals, Inc. (ETON) stock analysis on Invetso. Review Eton Pharmaceuticals, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.

Eton Pharmaceuticals, Inc. Company Overview

Eton Pharmaceuticals, Inc. Key Financial Metrics

About Eton Pharmaceuticals, Inc.

Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

Eton Pharmaceuticals, Inc. Investment Frameworks

Invetso analyzes Eton Pharmaceuticals, Inc. (ETON) across the following frameworks:

Explore More ETON Research